SWI/SNF Complex Alterations in Tumors with Rhabdoid Features: Novel Therapeutic Approaches and Opportunities for Adoptive Cell Therapy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Jul 14

PMID 37446319

Authors

Juan Jose Soto-Castillo

Lucia Llavata-Marti

Roser Fort-Culillas

Pablo Andreu-Cobo

Rafael Moreno

Carles Codony

Xavier Garcia Del Muro

Ramon Alemany

Josep M Piulats

Juan Martin-Liberal

Affiliations

Soon will be listed here.

Abstract

The SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodeling complex is one of the most remarkably altered epigenetic regulators in cancer. Pathogenic mutations in genes encoding SWI/SNF-related proteins have been recently described in many solid tumors, including rare and aggressive malignancies with rhabdoid features with no standard therapies in advanced or metastatic settings. In recent years, clinical trials with targeted drugs aimed at restoring its function have shown discouraging results. However, preclinical data have found an association between these epigenetic alterations and response to immune therapy. Thus, the rationale for immunotherapy strategies in SWI/SNF complex alteration-related tumors is strong. Here, we review the SWI/SNF complex and how its dysfunction drives the oncogenesis of rhabdoid tumors and the proposed strategies to revert this alteration and promising novel therapeutic approaches, including immune checkpoint inhibition and adoptive cell therapy.

Citing Articles

SMARCB1/INI-1-Deficient sinonasal carcinoma demonstrates a poor prognosis but favorable clinical outcomes after PD-1/PD-L1 inhibitor therapy: A case series.

Zhao S, Du H, Zhang Z, Yang J, Zhou Y, Xiao G Sci Prog. 2025; 108(1):368504251315075.

PMID: 39886754 PMC: 11783480. DOI: 10.1177/00368504251315075.

SWItch/Sucrose Nonfermentable complex-deficient pulmonary neoplasms: clinicopathologic characteristics and outcomes to radiotherapy and immunotherapy.

Gu Y, Lai S, Yang J, Zhang J, Fan X, Zheng Q Transl Lung Cancer Res. 2024; 13(10):2660-2672.

PMID: 39507018 PMC: 11535837. DOI: 10.21037/tlcr-24-339.

Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study.

Martin-Liberal J, Garralda E, Garcia-Donas J, Soto-Castillo J, Mussetti A, Codony C Future Oncol. 2024; 20(32):2437-2445.

PMID: 39129675 PMC: 11520549. DOI: 10.1080/14796694.2024.2385287.

Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.

Longo V, Catino A, Montrone M, Montagna E, Pesola F, Marech I Int J Mol Sci. 2024; 25(6).

PMID: 38542211 PMC: 10970296. DOI: 10.3390/ijms25063237.

References

Wiegand K, Shah S, Al-Agha O, Zhao Y, Tse K, Zeng T . ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010; 363(16):1532-43. PMC: 2976679. DOI: 10.1056/NEJMoa1008433. View

Pfister N, Fomin V, Regunath K, Zhou J, Zhou W, Silwal-Pandit L . Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev. 2015; 29(12):1298-315. PMC: 4495400. DOI: 10.1101/gad.263202.115. View

Rohaan M, Borch T, van den Berg J, Met O, Kessels R, Geukes Foppen M . Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med. 2022; 387(23):2113-2125. DOI: 10.1056/NEJMoa2210233. View

Le Loarer F, Zhang L, Fletcher C, Ribeiro A, Singer S, Italiano A . Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material. Genes Chromosomes Cancer. 2014; 53(6):475-86. PMC: 4226650. DOI: 10.1002/gcc.22159. View

Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay R, Luoma A . A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018; 359(6377):770-775. PMC: 5953516. DOI: 10.1126/science.aao1710. View

Chan-On W, Nairismagi M, Ong C, Lim W, Dima S, Pairojkul C . Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013; 45(12):1474-8. DOI: 10.1038/ng.2806. View

Napolitano M, Cipollaro M, Cascino A, Melone M, Giordano A, Galderisi U . Brg1 chromatin remodeling factor is involved in cell growth arrest, apoptosis and senescence of rat mesenchymal stem cells. J Cell Sci. 2007; 120(Pt 16):2904-11. DOI: 10.1242/jcs.004002. View

Orlando K, Nguyen V, Raab J, Walhart T, Weissman B . Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities. Expert Rev Anticancer Ther. 2019; 19(5):375-391. PMC: 6533634. DOI: 10.1080/14737140.2019.1605905. View

Miao D, Margolis C, Gao W, Voss M, Li W, Martini D . Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018; 359(6377):801-806. PMC: 6035749. DOI: 10.1126/science.aan5951. View

10.

Mashtalir N, DAvino A, Michel B, Luo J, Pan J, Otto J . Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling Complexes. Cell. 2018; 175(5):1272-1288.e20. PMC: 6791824. DOI: 10.1016/j.cell.2018.09.032. View

11.

Velez-Cruz R, Manickavinayaham S, Biswas A, Clary R, Premkumar T, Cole F . RB localizes to DNA double-strand breaks and promotes DNA end resection and homologous recombination through the recruitment of BRG1. Genes Dev. 2016; 30(22):2500-2512. PMC: 5159665. DOI: 10.1101/gad.288282.116. View

12.

Zhang J, Ohta T, Maruyama A, Hosoya T, Nishikawa K, Maher J . BRG1 interacts with Nrf2 to selectively mediate HO-1 induction in response to oxidative stress. Mol Cell Biol. 2006; 26(21):7942-52. PMC: 1636732. DOI: 10.1128/MCB.00700-06. View

13.

Michel B, DAvino A, Cassel S, Mashtalir N, McKenzie Z, McBride M . A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation. Nat Cell Biol. 2018; 20(12):1410-1420. PMC: 6698386. DOI: 10.1038/s41556-018-0221-1. View

14.

Gounder M, Schoffski P, Jones R, Agulnik M, Cote G, Villalobos V . Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020; 21(11):1423-1432. DOI: 10.1016/S1470-2045(20)30451-4. View

15.

Huang X, Park H, Greene J, Pao J, Mulvey E, Zhou S . IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. PLoS One. 2015; 10(7):e0133152. PMC: 4501840. DOI: 10.1371/journal.pone.0133152. View

16.

Jagani Z, Mora-Blanco E, Sansam C, McKenna E, Wilson B, Chen D . Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med. 2010; 16(12):1429-33. PMC: 3859448. DOI: 10.1038/nm.2251. View

17.

Gokden N, Nappi O, Swanson P, Pfeifer J, Vollmer R, Wick M . Renal cell carcinoma with rhabdoid features. Am J Surg Pathol. 2000; 24(10):1329-38. DOI: 10.1097/00000478-200010000-00002. View

18.

Oh J, Sohn D, Ko M, Chung H, Jeon S, Seong R . BAF60a interacts with p53 to recruit the SWI/SNF complex. J Biol Chem. 2008; 283(18):11924-34. DOI: 10.1074/jbc.M705401200. View

19.

Euskirchen G, Auerbach R, Davidov E, Gianoulis T, Zhong G, Rozowsky J . Diverse roles and interactions of the SWI/SNF chromatin remodeling complex revealed using global approaches. PLoS Genet. 2011; 7(3):e1002008. PMC: 3048368. DOI: 10.1371/journal.pgen.1002008. View

20.

de Castro R, Previato L, Goitea V, Felberg A, Guiraldelli M, Filiberti A . The chromatin-remodeling subunit Baf200 promotes homology-directed DNA repair and regulates distinct chromatin-remodeling complexes. J Biol Chem. 2017; 292(20):8459-8471. PMC: 5437250. DOI: 10.1074/jbc.M117.778183. View